Xponance Inc. Acquires 605 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Xponance Inc. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 9.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 7,350 shares of the biotechnology company’s stock after purchasing an additional 605 shares during the period. Xponance Inc.’s holdings in United Therapeutics were worth $2,593,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics during the fourth quarter worth about $25,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $33,000. MassMutual Private Wealth & Trust FSB boosted its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in shares of United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $131,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $388.25.

Insiders Place Their Bets

In related news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 90,255 shares of company stock worth $32,614,521 over the last 90 days. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 0.2 %

NASDAQ UTHR opened at $312.99 on Friday. The company has a market cap of $14.06 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The firm’s 50-day simple moving average is $345.10 and its two-hundred day simple moving average is $356.99.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the company posted $4.36 EPS. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.